Here we have a close look at some of the major Biotech Stocks which have shown tremendous promise over the past few weeks. Investors are all recommended to closely monitor these stocks over the coming months as some movement is expected from these stocks. Portola Pharmaceuticals (PTLA), a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. This stock closed up 4.1% … Continue reading Biotech Stocks in News: Major Biotech Stocks to Focus On

Mergers and acquisitions were back in the news last week with Auxilium Pharmaceuticals (AUXL) being the target this time around. The company, which is looking to acquire QLT Inc (QLTI), received a proposal from Endo International plc (ENDP). Other updates last week include the usual regulatory and pipeline-related news. Gilead remained in the news thanks yet again to its hepatitis C virus (HCV) treatment, Sovaldi. … Continue reading Biotech Stock News: A Weekly Analysis of Major Biotech Stocks

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading Halozyme’s Clinical Hold Lifted by FDA : Biotech

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading

Amgen (AMGN) announced that it has submitted a Biologics License Application (BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). The BLA includes positive data from a phase II study which evaluated the use of blinatumomab in adults with Ph- relapsed/refractory … Continue reading Major Biotech Stock in News: Amgen Files Blinatumomab Marketing Application

Shares of Gilead Sciences (GILD) declined approximately 0.9% to close the trading session on Sep 17 at $103.84 following a couple of setbacks — the failure of an oncology candidate to meet the primary endpoint in a phase II study and highly concerning data on the company’s blockbuster hepatitis C drug Sovaldi. Gilead’s pipeline candidate simtuzumab in combination with Eli Lilly and Company’s (LLY) Gemzar … Continue reading Biotech Stock Gilead Down Due To Weak Data Results